ATE241982T1 - Verfahren zur hemmung von diabetischen komplikationen - Google Patents

Verfahren zur hemmung von diabetischen komplikationen

Info

Publication number
ATE241982T1
ATE241982T1 AT99955093T AT99955093T ATE241982T1 AT E241982 T1 ATE241982 T1 AT E241982T1 AT 99955093 T AT99955093 T AT 99955093T AT 99955093 T AT99955093 T AT 99955093T AT E241982 T1 ATE241982 T1 AT E241982T1
Authority
AT
Austria
Prior art keywords
diabetic complications
instant invention
post
age formation
methods
Prior art date
Application number
AT99955093T
Other languages
English (en)
Inventor
John W Baynes
Suzanne R Thorpe
Thorsten P Degenhardt
Raja Gabriel Khalifah
Billy Hudson
Nathan Alderson
Original Assignee
Univ South Carolina
Kansas University Medical Ct R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina, Kansas University Medical Ct R filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE241982T1 publication Critical patent/ATE241982T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AT99955093T 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen ATE241982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10518298P 1998-10-22 1998-10-22
PCT/US1999/024611 WO2000023063A2 (en) 1998-10-22 1999-10-21 Methods for inhibiting diabetic complications

Publications (1)

Publication Number Publication Date
ATE241982T1 true ATE241982T1 (de) 2003-06-15

Family

ID=22304498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955093T ATE241982T1 (de) 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen

Country Status (8)

Country Link
EP (1) EP1121121B1 (de)
JP (1) JP3864050B2 (de)
AT (1) ATE241982T1 (de)
AU (2) AU762030B2 (de)
CA (1) CA2347117C (de)
DE (1) DE69908630T2 (de)
ES (1) ES2197689T3 (de)
WO (1) WO2000023063A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341532B1 (de) * 2000-11-02 2006-07-26 University of South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
CA2529538C (en) * 2003-06-20 2011-04-26 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
US7320988B2 (en) * 2003-10-27 2008-01-22 City Of Hope Methods of lowering lipid levels in a mammal
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
KR20080034845A (ko) * 2005-05-24 2008-04-22 토카이 유니버시티 에듀케이셔널시스템 복막보호제
EP2041114B1 (de) 2006-07-07 2016-03-02 NephroGenex, Inc. Hemmer fortgeschrittener Glykierungsendprodukte
WO2012011588A1 (ja) * 2010-07-23 2012-01-26 学校法人東海大学 腹膜透析患者用の経口医薬組成物及びその用法
JP6148127B2 (ja) * 2013-09-09 2017-06-14 株式会社パーマケム・アジア ピリドキサール・アミノグアニジン誘導体またはそれらの塩、及び、その製造方法
WO2016031839A1 (ja) * 2014-08-29 2016-03-03 株式会社プロジェクトPm ピリドキサミン化合物及びチアミン化合物を組み合わせてなる医薬組成物
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
WO2018048932A1 (en) * 2016-09-06 2018-03-15 Metabolic Technologies, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
EP4007632A1 (de) 2019-08-01 2022-06-08 Praetego, Inc. Hemmer von endprodukten verstärkter glykierungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH607773A5 (en) * 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
FR2349330A1 (fr) * 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
ES2078509T3 (es) * 1990-02-19 1995-12-16 Senju Pharma Co Composiciones inhibidoras de la reaccion de maillard.
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
JPH10158244A (ja) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd 5−アミノアルキル−4−アミノメチル−3−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
JPH10175954A (ja) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd 4−アミノメチル−3−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤

Also Published As

Publication number Publication date
CA2347117C (en) 2006-01-24
JP3864050B2 (ja) 2006-12-27
DE69908630T2 (de) 2004-04-29
ES2197689T3 (es) 2004-01-01
AU2003248205A1 (en) 2003-10-30
DE69908630D1 (de) 2003-07-10
EP1121121B1 (de) 2003-06-04
EP1121121A2 (de) 2001-08-08
WO2000023063A2 (en) 2000-04-27
AU762030B2 (en) 2003-06-19
JP2002527471A (ja) 2002-08-27
AU1127400A (en) 2000-05-08
CA2347117A1 (en) 2000-04-27
WO2000023063A3 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
DE69908630D1 (de) Verfahren zur hemmung von diabetischen komplikationen
EA200100702A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
ATE409037T1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69726815D1 (de) Verfahren zur Frakturierung von unterirdischen Lagerstätten
DE60101669D1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
DE69603089T2 (de) Zusammensetzung zur behandlung von mauerwerk
DE69806970D1 (de) Verfahren zur behandlung von hartgeweben
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
NO20011351D0 (no) FremgangsmÕte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
ATE426061T1 (de) Verfahren zur behandlung von textilen fasermaterialien
DE69631891D1 (de) Verfahren zur hemmung der bildung von hydraten
DE69904156D1 (de) Verfahren zur inhibierung der ablagerung von weisspech in der papierherstellung
DE60131545D1 (de) Verfahren zur behandlung von reaktiver arthritis oder schleimbeutelentzündung
WO2000021516A3 (en) Methods for inhibiting diabetic complications
DE69817080D1 (de) Verfahren zur Verminderung des Sauregehalts von Rohöl
DE69534118D1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
DE69409297T2 (de) Verfahren zur Vernetzung von Organosiloxanzusammensetzungen bei Anwesenheit von Vernetzungsinhibitoren
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
DE60221734D1 (de) Verfahren zur Verhinderung von Ablagerungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties